144 related articles for article (PubMed ID: 38595813)
1. Research progress of immunotherapy against anaplastic thyroid cancer.
Chen J; Xiao Z; Wu H
Front Oncol; 2024; 14():1365055. PubMed ID: 38595813
[TBL] [Abstract][Full Text] [Related]
2. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for anaplastic thyroid carcinoma: the present and future.
Lu X; Bao L; Pan Z; Ge M
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 50(6):675-684. PubMed ID: 35347912
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?
Gao X; Hong C; Xie Y; Zeng X
Front Oncol; 2023; 13():1103147. PubMed ID: 37007127
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in anaplastic thyroid cancer.
Ma M; Lin B; Wang M; Liang X; Su L; Okose O; Lv W; Li J
Am J Transl Res; 2020; 12(3):974-988. PubMed ID: 32269728
[TBL] [Abstract][Full Text] [Related]
6. Advances in targeted therapy for anaplastic thyroid carcinoma.
Qian C; Jiang L; Xu S; Wang J; Tan Z; Xin Y; Ge M
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 50(6):685-693. PubMed ID: 35347921
[TBL] [Abstract][Full Text] [Related]
7. Thyroid hormone receptor α1: a novel regulator of thyroid cancer cell differentiation.
Hwang E; Doolittle WKL; Zhu YJ; Zhu X; Zhao L; Yu Y; Cheng SY
Oncogene; 2023 Oct; 42(41):3075-3086. PubMed ID: 37634007
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials.
Li B; Jin J; Guo D; Tao Z; Hu X
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345194
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics.
Lu L; Wang JR; Henderson YC; Bai S; Yang J; Hu M; Shiau CK; Pan T; Yan Y; Tran TM; Li J; Kieser R; Zhao X; Wang J; Nurieva R; Williams MD; Cabanillas ME; Dadu R; Busaidy NL; Zafereo M; Navin N; Lai SY; Gao R
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37053016
[TBL] [Abstract][Full Text] [Related]
10. Increased tumor-associated mast cells facilitate thyroid cancer progression by inhibiting CD8+ T cell function through galectin-9.
Hou Y; Wang Q; Su L; Zhu Y; Xiao Y; Feng F
Braz J Med Biol Res; 2023; 56():e12370. PubMed ID: 37042867
[TBL] [Abstract][Full Text] [Related]
11. CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022.
Huang R; Wen Q; Zhang X
J Hematol Oncol; 2023 Apr; 16(1):35. PubMed ID: 37029381
[TBL] [Abstract][Full Text] [Related]
12. Therapy with oncolytic viruses: progress and challenges.
Shalhout SZ; Miller DM; Emerick KS; Kaufman HL
Nat Rev Clin Oncol; 2023 Mar; 20(3):160-177. PubMed ID: 36631681
[TBL] [Abstract][Full Text] [Related]
13. Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management.
Yuan J; Guo Y
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612173
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
